ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Novel Approach Based on Acceptor-Donor-Acceptor Type Molecules Enhances the Therapeutic Efficacy and Safety of Photothermal Therapy for Osteosarcoma.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Photothermal therapy based on acceptor-donor-acceptor (A-D-A) type molecules is emerging as a powerful clinical treatment strategy, yet its potential application in malignant osteosarcoma has been scarcely investigated. To resolve this, we constructed novel photothermal reagents from A-D-A molecules, boosting PCE of A-D-A photosensitizers by regulating intramolecular push-pull interactions. Through an optimized push-pull architecture, the IEICO-F molecule achieved an ideal overlap between its absorption spectrum and the 808 nm NIR laser, along with a high absorption coefficient and an increased nonradiative decay rate constant. Accordingly, following 5-min 808 nm laser exposure (0.33 W cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.